Companies › Bliss Biopharmaceutical (Hangzhou)
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BB-1709 | – | Phase 1 | Solid Tumor | Dec 2026 |
| BB-1705 Antibody-drug conjugate with humanized IgG1κ monoclonal antibody conjugated to eribulin vi | – | Phase 1 | Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05217693 | BB-1705 | Phase 1 | Solid Tumor | Oncology | Jun 2025 |
| NCT06241898 | BB-1709 | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.